A high-upside, asset-light gene-editing “trait factory” trying to survive the funding gap until 2027–2028 royalties ignite.
Overview
Cibus (CBUS) is a pure-play agricultural biotech licensor aiming to industrialize gene-edited trait development. Its RTDS platform and “Trait Machine” let seed-company partners submit elite germplasm, receive edited varieties on a predictable 12–15 month cycle, and pay recurring royalties once seeds are sold. The near-term value driver is the RISE rice program (HT traits addressing weed/red rice), targeting 5–7M peak acres in the U.S./Latin America and a potential >$200M annual royalty pool; longer-term upside includes global rice and a potentially massive EU opportunity if New Genomic Techniques (NGT) rules broaden access. A complementary Sustainable Ingredients segment (biofragrance) began receiving customer payments in late 2025. The opportunity is large and high-margin in theory, but the company is in a financially fragile pre-ramp phase with high burn, a large related-party royalty liability, and a going-concern warning—making 2026–2028 execution and funding the decisive variables.